Molecular analysis of 10 pleomorphic rhabdomyosarcomas reveals potential prognostic markers and druggable targets. Issue 3 (2nd December 2021)

• Record Type: Journal Article
• Authors: Chelsky, Zachary L.; Paulson, Vera A.; Chen, Eleanor Y.
• Is Part Of: Genes, chromosomes & cancer. Volume 61:Issue 3(2022)
• Page Start: 138
• Page End: 147
• Publication Date: 2021-12-02
• Subjects: expression -- mutations -- pleomorphic rhabdomyosarcoma -- prognosis -- therapy; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.23013
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Pleomorphic rhabdomyosarcoma (PRMS) is a rare and aggressive adult sarcoma with a median overall survival of less than 2 years. Most PRMS do not respond to conventional chemotherapy and/or radiation, and targeted therapies are nonexistent as few PRMS have undergone the molecular characterization necessary to identify therapeutic options. To date, complex structural and few recurrent regional copy alterations have been reported in the PRMS cases evaluated by cytogenetic and comparative genomic hybridization. Thus, there remains an urgent need for more comprehensive molecular profiling to both understand disease pathogenesis and to identify potentially actionable targets. Ten PRMS resection cases were retrieved from institutional archives and clinicopathologic demographics were recorded. All tumors were subjected to DNA‐based targeted next‐generation sequencing (NGS) of 340 cancer‐related genes while a subset (six cases) underwent gene‐expression profiling of 770 genes. Alterations identified by NGS included genes involved in cell cycle regulation (90%), the RAS/MAPK and AKT pathways (80%), telomere maintenance (40%), chromatin remodeling (40%), and DNA repair (20%), as well as the cAMP‐signaling pathway (10%). Microsatellite instability was absent in all cases, and tumor mutational burden was predominantly low. Gene expression profiling revealed up‐regulation of many of the same pathways, including the RTK/MAPK, AKT/PIK3CA/mTOR, Wnt, Hedgehog and JAK/STAT pathways. Survival analysis demonstrated patients with concurrent biallelic inactivation of CDKN2A and TP53 showed significantly shorter overall survival (median: 2 vs. 50 months). Our integrated molecular characterization identified not only potentially targetable alterations, but also prognostic markers for stratification of PRMS patients.